Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)

BACKGROUND: Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Cafferty, Fay H., White, Jeff D., Shamash, Jonathan, Hennig, Ivo, Stenning, Sally P., Huddart, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045084/
https://www.ncbi.nlm.nih.gov/pubmed/32007714
http://dx.doi.org/10.1016/j.ejca.2019.12.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045084/
https://www.ncbi.nlm.nih.gov/pubmed/32007714
http://dx.doi.org/10.1016/j.ejca.2019.12.028

Ejemplares similares